Showing 5171-5180 of 6036 results for "".
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- Americans See Hospitals as More Trustworthy Than FDA or CDC on COVID-19 Vaccine Information, Poll Findshttps://modernod.com/news/americans-see-hospitals-as-more-trustworthy-than-fda-or-cdc-on-covid-19-vaccine-information-poll-finds/2478225/When it comes to getting information about a future COVID-19 vaccine, Americans see hospitals as more trustworthy sources than federal agencies like the Food and Drug Administration or the Centers for Disease Control and Prevention (CDC), according to a new poll, as
- Practitioners Should Be Aware of Mask-Associated Dry Eye (MADE)https://modernod.com/news/core-alerts-practitioners-to-mask-associated-dry-eye-made/2478221/Widespread use of face masks has been determined essential to combat COVID-19’s spread, yet is giving rise to a new phenomenon: increased reports of dry eyes. Experts from the Centre for Ocular Research & Education (CORE) are advising eye care professionals on how to recognize mask-associated
- RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial in November 2020https://modernod.com/news/regenerx-joint-venture-expects-to-complete-phase-3-dry-eye-trial-in-november-2020/2478222/RegeneRx Biopharmaceuticals announced that its US joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. According to GtreeBNT, the ARISE-3 trial was delayed a few months due to COVID-19; h
- Hospitals Could Be Facing Lower Patient Volumes For a While due to COVID-19. How Are They Responding?https://modernod.com/news/hospitals-could-be-facing-lower-patient-volumes-for-a-while-due-to-covid-19-how-are-they-responding/2478223/Patient volumes at hospitals have rebounded after major dips in March and April due to the COVID-19 pandemic. But new data show they are still below pre-pandemic levels and could stay there for a while, according to a FierceHealthcare
- Topcon Announces the US Launch of Aladdin-Mhttps://modernod.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/Topcon Healthcare announced that it has launched its new Aladdin-M instrument in the US market. Aladdin-M combines corneal topography, pupillometry, and optical biometry to enable objective measurement of corneal curvature, pupil dynamics, and axial length metrics. The all-in-one Aladdin-M
- Vision Expo to Host Virtual Career Zone Event on September 22https://modernod.com/news/vision-expo-to-host-virtual-career-zone-event-on-september-22/2478215/Vision Expo announced plans to host the Virtual Career Zone, a virtual networking event designed to connect young professionals and students with prominent optical companies. Set to take place on Tuesday, September 22 from 11-11:55 a.m. EDT, the virtual event is inspired by Vision Expo’s o
- Moderna’s COVID-19 Vaccine Candidate Shows Promise in Older Adultshttps://modernod.com/news/modernas-covid-19-vaccine-candidate-shows-promise-in-older-adults/2478211/Interim data from a phase 1 study presented by Moderna showed that its experimental vaccine mRNA-1273 was safe and generated an immune response in people over the age of 55. Results from cohorts of older adults aged 56 to 70 years, as well as elderly participants 71 years and older, were detailed
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- Sight Sciences Announces Positive Interim Results From Trial of the OMNI Surgical System in Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-positive-interim-results-from-trial-of-the-omni-surgical-system-in-open-angle-glaucoma/2478205/Sight Sciences announced positive 6-month interim safety and efficacy results from a prospective, multicenter, historically controlled clinical trial of the OMNI Surgical System in open-angle glaucoma (OAG). The OMNI Surgical System is currently cleared for use for the delivery of small amounts o